Pharmaceutical

Alexandria Real Estate Equities has attained the world's first WELL Health-Safety Rating for laboratory space at Alexandria LaunchLabs in New York City. Augmenting the center’s existing WELL certification for building design, the WELL Health-Safety Rating for Facilities Operations and Management includes further measures to protect the health of tenants, employees, visitors, and service personnel. Protocols at Alexandria LaunchLabs include:

The University of Massachusetts Medical School is planning to construct the $325 million New Education and Research Building in Worcester. Accommodating 77 principal investigators, the nine-story, 350,000-sf facility will include space for animal research as well as housing an FDA-compliant manufacturing center for clinical trial therapeutics. The project will enable UMass to increase its class sizes help meet the needs of the commonwealth and the nation for physicians, graduate nurses, life sciences researchers, and other health sciences professionals.

The Centre for Process Innovation (CPI) began construction in October of 2020 on the Medicines Manufacturing Innovation Centre in Inchinnan in the United Kingdom. Created in collaboration with the University of Strathclyde, GSK, and AstraZeneca, the £42 million facility will enable the development of new pharmaceutical production methods that will be proven at scale in a GMP environment.

Merck is constructing a $69 million facility for the production of high-potency active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) compounds. Representing an expansion of the company's existing campus near Madison, the 70,000-sf structure will feature containment environments specifically designed for the manufacture of substances with single-digit nanogram occupational exposure limits. The building will allow the large-scale production of increasingly potent compounds for the creation of innovative cancer therapeutics.

Facility Logix, EwingCole, and Biggins Lacy Shapiro have launched Rapid Reshore & Development (RR&D) to provide turnkey professional services to the life sciences and biopharmaceutical industries. Addressing many of the logistical challenges faced by companies developing drugs, vaccines, and medical devices, the alliance represents an evolution from transaction-driven service models to a holistic focus on client needs.

Construction began in October of 2020 on the $44.2 million Discovery Square 2 building in Rochester, Minn. Designed by RSP Architects, the 125,000-sf facility will offer leasable research environments for life science companies. Sited in the Destination Medical Center district, the five-story structure will feature advanced laboratory infrastructure, centralized common spaces, and a physical connection to the adjacent One Discovery Square building.

Merck KGaA opened the $58.5 million Centre for Electronic Applications in September of 2020. Located on the company's headquarters campus in Darmstadt, Germany, the 118,400-sf facility will accelerate the discovery and development of next-generation materials for semiconductors and displays. Providing collaborative lab and office environments for 140 employees, the structure features a sophisticated building façade with dynamic liquid crystal windows that can be easily adjusted to minimize glare and heat gain. Construction began on the project in summer of 2017.

King Street Properties has fully leased a 214,440-sf research facility in Lexington, Mass., to four pharmaceutical companies. Designed by R E Dinneen Architects & Planners, the four-story building will offer leading-edge lab and office environments for biomedical research. JLL is the leasing agent for the development, which has yet to open. Tenants include:

Fujifilm Diosynth Biotechnologies broke ground in August of 2020 on the $55 million Advanced Therapies Innovation Center in College Station, Texas. Representing an expansion of Fujifilm's cGMP manufacturing campus, the 60,000-sf facility will feature dedicated labs for process development and innovation. Research environments with BSL-2 capabilities will integrate advanced technologies for upstream, downstream, and analytical development.

Codiak BioSciences is constructing a 12,000-sf clinical manufacturing center in Lexington, Mass. The project includes the build-out of a leased lab and office building to create a GMP facility for the production of exosome therapeutics. Codiak is incorporating G-CON Manufacturing's PODs into the center to provide flexible cleanroom capacity. The prefabricated units offer exceptional scalability and mobility, and can be easily repurposed to meet future needs.

CRISPR Therapeutics signed a full-building lease in July of 2020 for a 263,500-sf facility in Boston's Seaport district. Breakthrough Properties is the developer for the project, which was designed by Payette to provide best-in-class laboratory environments for life science research. Both LEED Gold and Fitwel certification will be sought for the structure, which will offer multiple amenities including outdoor terraces and a fitness center.

The Cell and Gene Therapy Catapult is planning to create the Manufacturing Innovation Centre in Braintree in the United Kingdom. Supported by £100 million in government funding, the project will enable mass production of a COVID-19 vaccine. An existing pharmaceutical plant has been purchased from Benchmark Holdings at a cost of £16 million. The structure's GMP infrastructure for antigen production, formulation, process development, and scale manufacturing will be repurposed and enhanced. Completion is expected in December of 2021.

DiNAQOR AG completed construction in July of 2020 on a 9,687-sf R&D center in Schlieren, Switzerland. Located in the Bio-Technopark Schlieren-Zürich, the BSL-2 facility will enable DiNAQOR to fast-track the development of its human-induced pluripotent stem cells (iPSC) and engineered heart tissue platform. Accelerating the creation of next-generation genetic medicine methodologies, the project also provides sophisticated infrastructure to further optimize the company's proprietary locoregional heart perfusion approach.

Winstanley Enterprises is planning to build a $100 million bioscience research building in New Haven, Conn. Designed by Elkus Manfredi Architects, the 10-story, 500,000-sf facility will provide leasable laboratory and office environments for life science companies and academic institutions. Featuring a large public plaza, the project will include a conference center, a 50,000-sf business incubator, and a classroom for K-12 educational programs.

MilliporeSigma, a subsidiary of Merck, is planning to expand its existing campus in Buchs, Switzerland, with the construction of a $20 million laboratory for the company's reference materials business. Accommodating 40 employees, the three-story, 12,000-sf structure will provide analytical and R&D suites for the testing of pharmaceuticals, environmental materials, and food and beverage products.